Authors' reply: "Risk reduction with buprenorphine-naloxone and methadone: patient's choice"

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):e142-3. doi: 10.1097/QAI.0000000000000344.

Authors

George Woody¹, Douglas Bruce, P Todd Korthuis, Sumedha Chhatre, Maureen Hillhouse, Petra Jacobs, James Sorensen, Andrew J Saxon, Sabrina Poole, David Metzger, Walter Ling

Affiliation

¹ *Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA †Treatment Research Institute, Philadelphia, PA ‡Yale University School of Medicine, New Haven, CT §Oregon Health and Science University, Portland, OR ‖University of California, Los Angeles, Los Angeles, CA ¶University of California, San Francisco, San Francisco, CA #Veterans Affairs Puget Sound Health Care System, Seattle, WA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

Buprenorphine / therapeutic use*
Female
HIV Infections / prevention & control*
Humans
Male
Methadone / therapeutic use*
Naloxone / therapeutic use*
Narcotic Antagonists / therapeutic use*
Opioid-Related Disorders / drug therapy*
Risk Reduction Behavior*

Substances

Narcotic Antagonists
Naloxone
Buprenorphine
Methadone

Grants and funding